imatinib mesylate has been researched along with chronic COVID syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, SS; Kow, CS; Ramachandram, DS | 1 |
1 other study(ies) available for imatinib mesylate and chronic COVID syndrome
| Article | Year |
|---|---|
Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19.
Topics: Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Imatinib Mesylate; Piperazines; Post-Acute COVID-19 Syndrome; Pyrimidines | 2023 |